Table 5.
Comparison between Negative and Positive JAK2 RS V617F Mutation Cases as Regards Demographic and Clinical Data
| Parameter | Wild JAK2 (No=72) No (%) | Mutant JAK2 (No=28) No (%) | P- Value | |
|---|---|---|---|---|
| Age (years) | Median (IQR) | 42.50 (19) | 60.0 (4) | |
| Min-max | 33-68 | 50-65 | 0.64 | |
| Sex | Male | 60 (83.3) | 24 (85.75) | 1 |
| Female | 12 (16.7) | 4 (14.3) | Fisher’s exact | |
| Organomegaly | Hepatomegaly | 30 (1.7) | 8 (28.6) | 0.22 (x2) |
| Splenomegaly | 58 (80.6) | 24 (85.7) | 0.54 (x2) | |
| Smoking | Positive | 9 (12.5) | 8 (28.6) | 0.13 (x2) |
| Hypertension | Present | 21 (27.6) | 7 (25) | 0.27 (x2) |
| DM | Present | 32 (44.4) | 14 (50) | 0.6 (x2) |
| Protein C | deficiency | 18 (25.0) | 10 (35.7) | 0.28 (x2) |
| Protein S | deficiency | 4 (5.6) | 6 (21.4) | 0.03* Fisher’s exact |
| ATIII | deficiency | 32 (44.4) | 20 (71.4) | 0.02 (x2) |
| FVL | Mutation | 12 (16.7) | 0 (0) | 0.01 (x2) |
| G20210A | Mutation | 2 (2.8) | 2 (7.1) | 0.57 (x2) |
| MTHFR | Heterozygous | 40 (55.6) | 2 (7.1) | <0.001 (x2) |
| LA | Positive | 10 (13.9) | 0 (0) | 0.06 * Fisher’s exact |
| ACL | Positive | 6 (8.3) | 2 (7.1) | 1.00* Fisher’s exact |
| Ascites | Absent | 26 (36.1) | 4 (14.3) | |
| Present | 46 (63.9) | 24 (85.7) | 0.03 (x2) | |
| History of DAAS | Positive | 40 (55.6) | 12 (42.9) | 0.29 Fisher’s exact |
| Tumor number: | Single | 24 (44.4) | 8 (36.45) | 0.51 (x2) |
| HCC cases (n=76) | Multiple | 30 (55.6) | 14 (63.6) | |
| Tumor size: | < 5 cm | 30 (55.6) | 16 (72.7) | 0.16 (x2) |
| HCC cases (n=76) | => 5 cm | 24 (44.4) | 6 (27.3) | |
| Child score: | A | 17 (23.6) | 7 (25) | |
| B | 23 (31.9) | 8 (28.6) | 0.12 (x2) | |
| C | 32 (44.5) | 13 (46.4) |
LA, lupus anticoagulant; ACL, anticardiolipin; DAAS, direct acting antiviral drugs; FVL, factor V Leiden; MTHFR, methyl-tetrahydrofolate reductase; P>0.05 is non-significant; p <0.05: is significant